Objective: Activated nuclear factor-ĸB is associated with the pathogenesis of numerous malignancies, including renal cell carcinoma (RCC). This study aimed to clarify the influence of a common insertion/deletion polymorphism (-94 ins/del ATTG, rs28362491) in the NFKB1 promoter on RCC susceptibility. Methods: We genotyped the NFKB1 -94 ins/del ATTG promoter polymorphism by the TaqMan method and assessed the association with RCC risk, clinicopathological parameters in a case-control study of 1,027 cases and 1,094 controls. Results: The genotype frequencies were significantly different between RCC cases and controls (p = 0.046). Compared with individuals carrying the ins/del + del/del genotypes, those with the ins/ins genotype had an increased RCC risk [p = 0.036, adjusted odds ratio (OR) = 1.23, 95% confidence interval (CI) = 1.02-1.48], particularly in the subgroup of younger age (p = 0.005, adjusted OR = 1.42, 95% CI = 1.11-1.83) and never smokers (p = 0.013, adjusted OR = 1.34, 95% CI = 1.07-1.69). Furthermore, the polymorphism was significantly associated with the risk of developing localized stage RCC (p = 0.020, OR = 1.26, 95% CI = 1.04-1.53). Conclusions: The functional NFKB1 promoter polymorphism is associated with an increased risk of RCC.

Keywords:
NFKB1 gene, Polymorphism, Renal cell carcinoma
1.
Siegel R, Ward E, Brawley O, Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-236.
2.
Chow WH, Dong LM, Devesa SS: Epidemiology and risk factors for kidney cancer. Nat Rev Urol 2010;7:245-257.
3.
Woldrich JM, Mallin K, Ritchey J, Carroll PR, Kane CJ: Sex differences in renal cell cancer presentation and survival: an analysis of the National Cancer Database, 1993-2004. J Urol 2008;179:1709-1713.
4.
Hirata H, Hinoda Y, Nakajima K, et al: The bcl2 -938CC genotype has poor prognosis and lower survival in renal cancer. J Urol 2009;18:721-727.
5.
Lin J, Horikawa Y, Tamboli P, Clague J, Wood CG, Wu X: Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma. Carcinogenesis 2010;31:1805-1812.
6.
Kleinrath T, Gassner C, Lackner P, Thurnher M, Ramoner R: Interleukin-4 promoter polymorphisms: a genetic prognostic factor for survival in metastatic renal cell carcinoma. J Clin Oncol 2007;25:845-851.
7.
Kawai Y, Sakano S, Korenaga Y, Eguchi S, Naito K: Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas. Eur Urol 2007;52:1147-1155.
8.
Sen R, Baltimore D: Inducibility of kappa immunoglobulin enhancer-binding protein NF-kappa B by a posttranslational mechanism. Cell 1986;47:921-928.
9.
Baldwin AS Jr: The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-683.
10.
Pahl HL: Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999;18:6853-6866.
11.
Cao Y, Karin M: NF-kappaB in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia 2003;8:215-223.
12.
Camp ER, Li J, Minnich DJ, et al: Inducible nuclear factor-kappaB activation contributes to chemotherapy resistance in gastric cancer. J Am Coll Surg 2004;199:249-258.
13.
Ni J, Takayama K, Inoshima N, et al: Gene transfer of inhibitor kappaB in human lung cancer cell line NCI-H460 inhibits tumorigenesis and angiogenesis in vivo. Anticancer Res 2005;25:69-77.
14.
Salvatore C, Camarda G, Maggi CA, Goso C, Manzini S, Binaschi M: NFkappaB activation contributes to anthracycline resistance pathway in human ovarian carcinoma cell line A2780. Int J Oncol 2005;27:799-806.
15.
Dajee M, Lazarov M, Zhang JY, et al: NF-kB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 2005;421:639-643.
16.
Baldwin AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kB. J Clin Invest 2001;107:241-246.
17.
Oya M, Takayanagi A, Horiguchi A, et al: Increased nuclear factor-kB activation is related to the tumor development of renal cell carcinoma. Carcinogenesis 2003;24:377-384.
18.
Chen F, Castranova V, Shi X, Demers LM: New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 1999;45:7-17.
19.
Lin L, DeMartino GN, Greene WC: Cotranslational biogenesis of NF-kB p50 by the 26S proteasome. Cell 1998;92:819-828.
20.
Zhang P, Wei Q, Li X, et al: A functional insertion/deletion polymorphism in the promoter region of the NFKB1 gene increases susceptibility for prostate cancer. Cancer Genet Cytogenet 2009;191:73-77.
21.
Lo SS, Chen JH, Wu CW, Lui WY: Functional polymorphism of NFKB1 promoter may correlate to the susceptibility of gastric cancer in aged patients. Surgery 2009;145:280-285.
22.
Tang T, Cui S, Deng X, et al: Insertion/deletion polymorphism in the promoter region of NFKB1 gene increases susceptibility for superficial bladder cancer in Chinese. DNA Cell Biol 2009;28:1-4.
23.
Burnik FS, Yalcin S: NFKB1 -94 insertion/deletion ATTG polymorphism in gastroenteropancreatic neuroendocrine tumors. Chemotherapy 2009;55:381-385.
24.
Lehnerdt GF, Bankfalvi A, Grehl S, et al: No association of the NF-kappaB1 -94ins/delATTG promoter polymorphism with relapse-free and overall survival in patients with squamous cell carcinomas of the head and neck region. Int J Immunopathol Pharmacol 2008;21:827-832.
25.
Riemann K, Becker L, Struwe H, Rubben H, Eisenhardt A, Siffert W: Insertion/deletion polymorphism in the promoter of NFKB1 as a potential molecular marker for the risk of recurrence in superficial bladder cancer. Int J Clin Pharmacol Ther 2007;45:423-430.
26.
Riemann K, Becker L, Struwe H, et al: No association of the NFKB1 insertion/deletion promoter polymorphism with survival in colorectal and renal cell carcinoma as well as disease progression in B-cell chronic lymphocytic leukemia. Pharmacogenet Genomics 2006;16:783-788.
27.
Zhou B, Rao L, Li Y, et al: A functional insertion/deletion polymorphism in the promoter region of NFKB1 gene increases susceptibility for nasopharyngeal carcinoma. Cancer Lett 2009;275:72-76.
28.
Lewander A, Butchi AK, Gao J, et al; Swedish Low-Risk Colorectal Cancer Study Group: Polymorphism in the promoter region of the NFKB1 gene increases the risk of sporadic colorectal cancer in Swedish but not in Chinese populations. Scand J Gastroenterol 2007;42:1332-1338.
29.
Bu H, Rosdahl I, Sun XF, Zhang H: Importance of polymorphisms in NF-kappaB1 and NF-kappaBIalpha genes for melanoma risk, clinicopathological features and tumor progression in Swedish melanoma patients. J Cancer Res Clin Oncol 2007;133:859-866.
30.
Lin SC, Liu CJ, Yeh WI, Lui MT, Chang KW, Chang CS: Functional polymorphism in NFKB1 promoter is related to the risks of oral squamous cell carcinoma occurring on older male areca (betel) chewers. Cancer Lett 2007;243:47-54.
31.
Zou YF, Yuan FL, Feng XL, et al: Association between NFKB1 -94ins/delATTG promoter polymorphism and cancer risk: a meta-analysis. Cancer Invest 2011;29:78-85.
32.
Qin C, Cao Q, Ju X, et al: The polymorphisms in the VHL and HIF1A genes are associated with the prognosis but not the development of renal cell carcinoma. Ann Oncol 2012;23:981-989.
33.
Karban AS, Okazaki T, Panhuysen CI, et al: Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 2004;13:35-45.
34.
Li H, Gao L, Shen Z, et al: Association study of NFKB1 and SUMO4 polymorphisms in Chinese patients with psoriasis vulgaris. Arch Dermatol Res 2008;300:425-433.
35.
Sourbier C, Danilin S, Lindner V, et al: Targeting the nuclear factor-kappaB rescue pathway has promising future in human renal cell carcinoma therapy. Cancer Res 2007;67:11668-11676.
36.
Meteoglu I, Erdogdu IH, Meydan N, Erkus M, Barutca S: NF-KappaB expression correlates with apoptosis and angiogenesis in clear cell renal cell carcinoma tissues. J Exp Clin Cancer Res 2008;27:53.
37.
Djordjevic G, Matusan-Ilijas K, Sinozic E, et al: Relationship between vascular endothelial growth factor and nuclear factorkappaB in renal cell tumors. Croat Med J 2008;49:608-617.
38.
Konda R, Sugimura J, Sohma F, et al: Overexpression of hypoxia-inducible protein 2, hypoxia-inducible factor 1alpha and nuclear factor kappaB is putatively involved in acquired renal cyst formation and subsequent tumor transformation in patients with end stage renal failure. J Urol 2008;180:481-485.
39.
Kim W, Kaelin WG Jr: The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Curr Opin Genet Dev 2003;13:55-60.
40.
Sen R, Baltimore D: Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986;46:705-716.
41.
Li X, Liu J, Park JK, et al: T cells from renal cell carcinoma patients exhibit an abnormal pattern of kappa B-specific DNA-binding activity: a preliminary report. Cancer Res 1994;54:5424-5429.
42.
Kim HJ, Park JK, Kim YG: Suppression of NF-kappaB activation in normal T cells by supernatant fluid from human renal cell carcinomas. J Korean Med Sci 1999;14:299-303.
43.
Thornton MV, Kudo D, Rayman P, et al: Degradation of NF-kappa B in T cells by gangliosides expressed on renal cell carcinomas. J Immunol 2004;172:3480-3490.
44.
Cao Q, Qin C, Meng X, et al: Genetic polymorphisms in APE1 are associated with renal cell carcinoma risk in a Chinese population. Mol Carcinog 2011;50:863-870.
45.
Lin J, Pu X, Wang W, et al: Case-control analysis of nucleotide excision repair pathway and the risk of renal cell carcinoma. Carcinogenesis 2008;29:2112-2119.
46.
Terry PD, Umbach DM, Taylor JA: APE1 genotype and risk of bladder cancer: evidence for effect modification by smoking. Int J Cancer 2006;118:3170-3173.
47.
Hazra A, Chamberlain RM, Grossman HB, Zhu Y, Spitz MR, Wu X: Death receptor 4 and bladder cancer risk. Cancer Res 2003;63:1157-1159.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.